Page 40 - Heca News Today

Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents.

Gilead Sciences Inc on Tuesday unveiled data from the first human study of its experimental oral COVID-19 antiviral, saying the results in healthy volunteers cleared the way for two large Phase III trials of the drug that have begun enrolling patients.

The U.S. National Institute on Aging (NIA) is funding a 6-year, up to $300 million project to build a massive Alzheimer's research database that can track the health of Americans for decades and enable researchers to gain new insights on the brain-wasting disease.

The EU is revamping laws governing the 136 billion euro ($148 billion) pharmaceuticals industry aimed at reviving investment and boosting access to affordable drugs at a time when health budgets have been drained by the costs of treating COVID-19.

Japan's Prime Minister Fumio Kishida said on Monday the government will continue to strongly demand Beijing for an early release and consular visits for an Astellas Pharma employee detained in China.

Major stock markets in the Gulf rose in early trade on Monday, tracking oil prices higher following a surprise announcement by OPEC+ to cut more production.

Temasek, the sovereign wealth fund of Singapore and a major shareholder in Bayer , will back re-election of the German pharmaceuticals company's supervisory board chair, the Wirtschaftswoche news outlet reported on Monday, citing unnamed sources.

Florida's Republican-led Senate passed a bill on Monday to outlaw most abortions after six weeks of pregnancy, bringing the state a step closer to joining others across the U.S. South in banning almost all abortions.

About one in six adults globally have experienced infertility at least once in their life, the World Health Organization (WHO) said in a report on Monday, urging countries to actively collect more consistent data on the disease.

Cytokinetics Inc said on Friday it would focus on its heart disease treatment after its amyotrophic lateral sclerosis (ALS) drug failed a late-stage study.